Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03956615 Recruiting - Multiple Myeloma Clinical Trials

sdAb-based TRNT of Multiple Myeloma: a Feasibility Study

Start date: February 12, 2019
Phase: N/A
Study type: Interventional

This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.

NCT ID: NCT03952091 Recruiting - Clinical trials for Refractory Multiple Myeloma

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: March 27, 2019
Phase: Phase 3
Study type: Interventional

A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment

NCT ID: NCT03951220 Recruiting - Myeloma Clinical Trials

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

Start date: March 29, 2018
Study type: Observational

In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density.

NCT ID: NCT03948035 Recruiting - Clinical trials for Newly Diagnosed Multiple Myeloma

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Start date: August 28, 2018
Phase: Phase 3
Study type: Interventional

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to significantly prolong PFS in this patient cohort with a greater proportion of patients in at least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of infusion-related reactions with this specific moAb was very low, with an overall rate of 10% in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related reactions. Of particular interest is the observation in this trial, that response and PFS were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other drug-based approaches. The investigators assume that incorporating the moAb into the KRd triple induction regimen should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response [VGPR] as defined by the International Myeloma Working Group [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather than complete response (CR) to exclude false-positive immunofixation results. Furthermore the investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS further.

NCT ID: NCT03940833 Recruiting - Multiple Myeloma Clinical Trials

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Start date: May 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

NCT ID: NCT03937635 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

NCT ID: NCT03931421 Recruiting - Multiple Myeloma Clinical Trials

B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

It's a single arm, open label prospective study, in which the safety and efficacy of B Cell Maturation Antigen(BMCA)-targeted CAR-T thearpy are evaluated in refractory/relapsed multiple myeloma patients.

NCT ID: NCT03908138 Recruiting - Multiple Myeloma Clinical Trials

RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma

Start date: March 30, 2019
Phase: Phase 4
Study type: Interventional

Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM patients. However, ASCT therapy in young patients with MM is still important. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs also play a variety of immune regulatory roles. Lenalidomide, a kind of IMiDs, was usually used in the therapy of relapsed/refractory MM. The efficacy and safety of RDD (lenalidomide, pegylated liposomal doxorubicin, dexamethasone) followed by ASCT in newly diagnosed young patients with MM still needs to be further validated.

NCT ID: NCT03890614 Recruiting - Multiple Myeloma Clinical Trials

Novel 3D Myeloma Organoid to Study Disease Biology and Chemosensitivity

Start date: May 16, 2019
Study type: Observational

The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed multiple myeloma and potentially other cancers.

NCT ID: NCT03875495 Recruiting - Multiple Myeloma Clinical Trials

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment.